---
figid: PMC9178120__fonc-12-899272-g005
figtitle: Contribution of the Tumor Microenvironment to Metabolic Changes Triggering
  Resistance of Multiple Myeloma to Proteasome Inhibitors
organisms:
- Homo sapiens
- Mus musculus
- Enterovirus C
organisms_ner:
- Mus musculus
- Homo sapiens
- Drosophila melanogaster
pmcid: PMC9178120
filename: fonc-12-899272-g005.jpg
figlink: /pmc/articles/PMC9178120/figure/f5/
number: F5
caption: Metabolic factors promoting resistance to PI in MM. (A) Adaptive cellular
  responses following acute and short-term PI treatment. (B) Global cellular adaptation
  towards PI treatment (emerging as the PI resistance). ATF4, activating transcription
  factor 4; BiP, binding immunoglobulin protein; CLR, calreticulin; CNX, calnexin;
  ER, endoplasmic reticulum; FAM46C, family with sequence similarity 46 member C;
  G-6-P, glucose-6-phosphate; GCN2, general control nonderepressible 2; Gln, glutamine;
  GLS, glutaminase; Glu, glucose; GLUT, glucose transporter; GSH, glutathione (reduced);
  GSSG, glutathione (oxidized); GSTP, Glutathione S-transferase P; KLF4, kruppel like
  factor 4; LC3, protein light chain 3; mTORC, mechanistic target of rapamycin complex
  1; NAD(P)+/H, nicotinamide adenine dinucleotide (phosphate) oxidized/reduced); NRF2,
  nuclear factor erythroid 2-related factor 2; OXPHOS, oxidative phosphorylation;
  PDI, protein disulfide isomerase; 3-PG, 3-phosphoglyceric acid; PHGDH, phosphoglycerate
  dehydrogenase; PI, proteasome inhibitor; PPP, pentose phosphate pathway; REDOX,
  reduction–oxidation; SERCA, sarco/endoplasmic reticulum Ca2+-ATPase; SLC1A5, solute
  carrier family 1 member 5; SLC7A11, solute carrier family 7 member 11; SSG, S-glutathionylation;
  SSP, serine synthesis pathway; SQSTM1, sequestosome 1; TCA, tricarboxylic acid;
  Ub, ubiquitin; UFD1L, ubiquitin recognition factor in ER associated degradation;
  UPR, unfolded protein response; VCP, valosin-containing protein.
papertitle: Contribution of the Tumor Microenvironment to Metabolic Changes Triggering
  Resistance of Multiple Myeloma to Proteasome Inhibitors.
reftext: Jonas Schwestermann, et al. Front Oncol. 2022;12:899272.
year: '2022'
doi: 10.3389/fonc.2022.899272
journal_title: Frontiers in Oncology
journal_nlm_ta: Front Oncol
publisher_name: Frontiers Media S.A.
keywords: multiple myeloma | tumor microenvironment | proteasome inhibitors | resistance
  | metabolism
automl_pathway: 0.9436463
figid_alias: PMC9178120__F5
figtype: Figure
redirect_from: /figures/PMC9178120__F5
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC9178120__fonc-12-899272-g005.html
  '@type': Dataset
  description: Metabolic factors promoting resistance to PI in MM. (A) Adaptive cellular
    responses following acute and short-term PI treatment. (B) Global cellular adaptation
    towards PI treatment (emerging as the PI resistance). ATF4, activating transcription
    factor 4; BiP, binding immunoglobulin protein; CLR, calreticulin; CNX, calnexin;
    ER, endoplasmic reticulum; FAM46C, family with sequence similarity 46 member C;
    G-6-P, glucose-6-phosphate; GCN2, general control nonderepressible 2; Gln, glutamine;
    GLS, glutaminase; Glu, glucose; GLUT, glucose transporter; GSH, glutathione (reduced);
    GSSG, glutathione (oxidized); GSTP, Glutathione S-transferase P; KLF4, kruppel
    like factor 4; LC3, protein light chain 3; mTORC, mechanistic target of rapamycin
    complex 1; NAD(P)+/H, nicotinamide adenine dinucleotide (phosphate) oxidized/reduced);
    NRF2, nuclear factor erythroid 2-related factor 2; OXPHOS, oxidative phosphorylation;
    PDI, protein disulfide isomerase; 3-PG, 3-phosphoglyceric acid; PHGDH, phosphoglycerate
    dehydrogenase; PI, proteasome inhibitor; PPP, pentose phosphate pathway; REDOX,
    reduction–oxidation; SERCA, sarco/endoplasmic reticulum Ca2+-ATPase; SLC1A5, solute
    carrier family 1 member 5; SLC7A11, solute carrier family 7 member 11; SSG, S-glutathionylation;
    SSP, serine synthesis pathway; SQSTM1, sequestosome 1; TCA, tricarboxylic acid;
    Ub, ubiquitin; UFD1L, ubiquitin recognition factor in ER associated degradation;
    UPR, unfolded protein response; VCP, valosin-containing protein.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Nfe2l2
  - Gtf2h1
  - Nup62
  - Sqstm1
  - Khdrbs1
  - Dctn4
  - 20S
  - Ufd1
  - Ccn3
  - Plxna1
  - Hspa5
  - Canx
  - Calcr
  - Vcp
  - Tent5c
  - Pdia3
  - P4hb
  - Padi2
  - Map1lc3a
  - Akt1
  - Ar
  - Phgdh
  - Spe1r
  - Gnat2
  - Slc1a3
  - Slc2a1
  - Slc2a4
  - Slc1a5
  - Slc7a11
  - PSMA1
  - PSMA2
  - PSMA3
  - PSMA4
  - PSMA5
  - PSMA6
  - PSMA7
  - PSMA8
  - PSMB1
  - PSMB10
  - PSMB2
  - PSMB3
  - PSMB4
  - PSMB5
  - PSMB6
  - PSMB7
  - PSMB8
  - PSMB9
  - PSMC1
  - PSMC2
  - PSMC3
  - PSMC4
  - PSMC5
  - PSMC6
  - PSMD1
  - PSMD10
  - PSMD11
  - PSMD12
  - PSMD13
  - PSMD14
  - PSMD2
  - PSMD3
  - PSMD4
  - PSMD5
  - PSMD6
  - PSMD7
  - PSMD8
  - PSMD9
  - PSME1
  - PSME2
  - PSME3
  - PSMF1
  - SEM1
  - USP5
  - GABPA
  - NFE2L2
  - GTF2H1
  - SQSTM1
  - KHDRBS1
  - NUP62
  - DCTN4
  - GSTP1
  - UFD1
  - CCN3
  - PLXNA1
  - RPL10
  - GDF10
  - HSPA5
  - CANX
  - DCLK3
  - ATP2A1
  - ATP2A2
  - ATP2A3
  - VCP
  - TENT5C
  - P4HB
  - PADI1
  - PDIA2
  - MAP1LC3A
  - AKT1
  - AKT2
  - AKT3
  - AR
  - PHGDH
  - SLC2A1
  - SLC2A4
  - SLC1A5
  - SLC7A11
  - Keap1
  - cnc
  - ref(2)P
  - DCTN4-p62
  - Tfb1
  - Taf6
  - how
  - S(CycE[JP])20S1
  - fs(1)Yb
  - bip
  - Hsc70-3
  - Cnx14D
  - Cnx99A
  - Calr
  - SERCA
  - TER94
  - Sh
  - Pdi
  - Atg8a
  - Akt
  - Crtc
  - ar
  - ssp
  - Glut1
---
